Volume 181 - Issue 8

The medical profession and the pharmaceutical industry: when will we open our eyes?

Author:  Tim Woodruff

Med J Aust 2004; 181 (8): 458-459. || doi: 10.5694/j.1326-5377.2004.tb06380.x
Published online: 18 October 2004

To the Editor: It is encouraging to see the Journal continuing its tradition of taking on contentious issues in publishing articles about the negative influence of the pharmaceutical industry.1 With respect to the practical suggestions to address this issue, I suggest that reliance on our profession to substantially improve the situation, although laudable and appropriate, is too optimistic given the gross denial by our colleagues that there is an issue. Our professional bodies simply do not have the support to enforce codes of conduct. The Royal Australasian College of Physicians (RACP) has published guidelines on this issue,2 but I doubt most of its members have read them.

I fully support Breen’s comments relating to funding of educational activities, but I suggest that the pharmaceutical pseudo-educational dollar be bypassed by a major expansion in government funding.3 The provision of regularly updated, easily accessible treatment guidelines integrated into prescribing software (which most general practitioners use daily) would go a long way to decreasing our reliance on the drug dollar for information on appropriate treatment. This requires government investment and professional college cooperation, but would lead to recurrent savings to the Pharmaceutical Benefits Scheme and better treatment.

Currently, the federal government spends $21 million on drug information to doctors,4 while the drug industry spends $1 billion on marketing.5 To partially redress this imbalance would, however, require both political will and pressure from the profession.


Author


References